CTIS2023-506126-36-00进行中（未招募）1 期
MinoPro-101
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single Ascending and Multiple Ascending Doses of Prosetin in Healthy Volunteers and Participants with Amyotrophic Lateral Sclerosis (ALS) with an Optional Open-Label Extended Treatment Period for ALS Participants who Complete 14 Days of Blinded TreatmentCTIS2023-507363-20-00Projenx Inc.24
招募中
1 期
A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD) patientsAlzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease (HD), Multiple Sclerosis (MS)MedDRA version: 20.0Level: PTClassification code: 10070668Term: Huntington's disease Class: 100000004850MedDRA version: 20.0Level: LLTClassification code: 10001896Term: Alzheimer's disease Class: 10029205MedDRA version: 21.1Level: PTClassification code: 10002026Term: Amyotrophic lateral sclerosis Class: 100000004852MedDRA version: 20.1Level: PTClassification code: 10028245Term: Multiple sclerosis Class: 100000004852CTIS2023-507195-43-00Mitochon Pharmaceuticals Inc.40
进行中（未招募）
不适用
未命名试验-MedDRA version: 16.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2012-004463-41-PTMedica Scientia Innovation Research (MedSIR ARO)60
进行中（未招募）
不适用
未命名试验-MedDRA version: 15.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2012-004463-41-ESMedica Scientia Innovation Research (MedSIR ARO)60
招募中
1 期
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid TumorsCTIS2023-505576-29-00Centessa Pharmaceuticals UK Limited180